![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2020 07:36 | You beat me Crookie | ![]() royalalbert | |
23/4/2020 07:36 | Here's the link for Birmingham NHS. | ![]() royalalbert | |
23/4/2020 07:35 | See for yourself Nobby: hxxps://www.uhb.nhs. Looks quite clear although we don’t know how many they were allocated could have been 5! I doubt it though Birmingham likely to be one of the larger ones. | ![]() crookie3634 | |
23/4/2020 07:34 | >> jm4910 The short answer is yes. I strongly suspect conditional approval will come on the back of a positive result but there is certainly no guarantee. I suspect they would license the drug to a major Pharma under the phase III scenario to expedite the trial which will cost £10 million plus. So that would be seen as s strong positive too so plenty of value here whatever happens. All just IMHO and DYOR... | ![]() nobbygnome | |
23/4/2020 07:18 | >> crookie Amazing news if true, although I am somewhat sceptical! | ![]() nobbygnome | |
23/4/2020 07:16 | Someone on LSE found this posted on Birmingham NHS trust website: Two further trials, RECOVERY and SGO16, are investigating the use of different drugs, currently being used for other diseases, to see if they could benefit patients with COVID-19. RECOVERY (Randomised Evaluation of COVid-19 thERapY) is testing a number of drugs, with regular reviews based on updated clinical evidence to add or remove drugs from the trial. SG016, which looked at the effectiveness of a drug, SNG001, in improving lung function for patients with COVID-19, was able to finish recruitment within a week. Initial results from all trials are expected within weeks. Looks like they are all done there and just waiting for results. Suggests recruitment has gone really well, really positive find. | ![]() crookie3634 | |
23/4/2020 07:01 | Exactly- what a total clown | ![]() imjustdandy | |
23/4/2020 07:01 | Pro , stick to oil companies | ![]() tialouise | |
23/4/2020 06:51 | From the article you posted. Here's an extract. 1. Respiratory- main cause of deathAlthough acute respiratory distress syndrome (ARDS) still appears to be the leading cause of death in Covid 19 patients, blood complications are not far away, said Behnood Bikdeli, a fourth-year fellow at Columbia University's Irving Medical Center, who was anchoring a Article about the blood clot in the Journal of the American College of Cardiology. | ![]() imjustdandy | |
23/4/2020 06:46 | If you care to read the studies from China you will see the main issue is respiratory first and foremost. The clotting appears to be linked to obesity, diabetes and heart disease. Treating the respiratory issues are first and foremost but the complications of blood clotting appear to come from "underlying health issues" . | ![]() imjustdandy | |
23/4/2020 06:39 | Pulmonary failure caused by..........Micro-bl . | pro_s2009 | |
23/4/2020 06:29 | Clotting factors and organ failures are still "minimal compared to the main general aspects of really severe pulmonary failure," says Shabah. "So respiratory failure that happens is the main thing that worries us." | ![]() imjustdandy | |
23/4/2020 06:06 | Indeed.......that is one "cure"..........it may so turn out to be. They were looking as to why Coronary Artery Disease is a leading underlying cause of Covid-19 death, but Asthma is not. Surely if its a lung disease then smokers and those with Asthma should be up there in high percentiles. But they are not. Studies all over the place (based on real data and not supposition) show smoking and Asthma unrelated to any increase in Covid-19 severity or death in the real world. So now it seems the lungs are getting blocked by micro-blood clots, this is causing the low blood oxygen levels and other problems. No need to treat the lungs, need to treat the blood clotting. | pro_s2009 | |
23/4/2020 05:52 | Just take Aspirin :-) | ![]() amaretto1 | |
23/4/2020 04:34 | Very interesting. The reason it seems that the Ventilator issue is now being swept under the carpet and the curve ball of more PPE is hot in the media is that its no longer considered to be a lung disease and mechanical ventilation has been killing people. It now seems the issue is blood clotting. Lungs are full of micro-blood clots. Now everyone looking at blood thinners and anticoagulants and treating blood disease. . | pro_s2009 | |
22/4/2020 23:34 | Nobbygnome you might be best to answer this. SNG016 is a phase 2 trial, is there any risk this wouldn't be rolled out asap (if successful) because we haven't done a phase 3 trial? | jm4910 | |
22/4/2020 23:05 | Amaretto, I might have received an apology from you. Just like a politician, you post again and talk about something else | ![]() lukead | |
22/4/2020 22:21 | I know every thing there is in the public domain I'm invested here, and it's in my interests to know about the drug... and the risks... which i see at 60/40 in our favour at present. | ![]() amaretto1 | |
22/4/2020 22:15 | Yes bought a pulse oxometer too. Arrived today. Please lets find a decent treatment. The medics might enjoy the social distancing theory but it will destroy society | glennrcharles | |
22/4/2020 22:14 | We need a drug to get the country moving . SNG will hopefully be the saviour | ![]() imjustdandy |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions